Selleck Chemicals - Model A2520 -Demcizumab (Anti-DLL4)

Demcizumab (Anti-DLL4) is a monoclonal antibody taregting DLL4. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models. MW: 145.5 KD.